Screening MRI Scan for the Imaging of Metastatic, Unresectable, or Recurrent Breast Cancer

Inclusion Criteria

• Participants must have histologically or cytologically confirmed breast cancer with pathologic assessment of estrogen receptor (ER), progesterone receptor (PR), and HER2. If subtype has changed over the course of a patient’s disease, the treating clinician and/or study principal investigator (PI) is responsible for selecting the subtype that most likely reflects the preponderance of oncologic disease at the time of enrollment
• Participants must have radiographic evidence of extracranial, distant metastases or unresectable, locally recurrent breast cancer and be receiving first-line through fourth-line chemotherapy for their metastatic/recurrent disease (for the HR+/HER2- cohort patients must be receiving first-line through fourth-line systemic therapy of any nature after progression on or discontinuation of a CDK4/6 inhibitor) OR inflammatory breast cancer being managed with curative intent within one year of diagnosis
• Participants must be age 18 years or older
• Participants must have a life expectancy of greater than 12 weeks
• Participants must be willing to undergo study procedures
• The effects of gadolinium / other MRI-based contrast agents on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately
• Participants must possess the ability to understand and the willingness to sign a written informed consent document, via ink on paper or via an electronic signature medium such as Adobe Sign

Exclusion Criteria

• Participants who have a contraindication to MRI (e.g. noncompatible implanted metallic device for which MRI is absolutely contraindicated)
• Participants who have chronic kidney disease stage IV-V (EGFR < 30) or end stage renal disease
• Participants with a history of anaphylactic reactions to gadolinium
• Pregnant women are excluded from this study because gadolinium-based agents have not been proven to be safe to administer to a developing fetus. Similarly, breastfeeding women will be excluded from this study
• Patients with a prior diagnosis of brain metastases